NASDAQ:MIRA MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis $0.66 +0.01 (+1.77%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.65 -0.01 (-1.03%) As of 11/13/2026 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About MIRA Pharmaceuticals Stock (NASDAQ:MIRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MIRA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.61▼$0.6650-Day Range$0.52▼$0.9152-Week Range$0.51▼$1.69Volume90,858 shsAverage Volume151,561 shsMarket Capitalization$27.72 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingHold Company Overview MIRA Pharmaceuticals is a clinical-stage pharmaceutical company developing oral drug candidates for neurological and neuropsychiatric conditions. Its pipeline includes MIRA1a, an investigational synthetic cannabinoid analog being studied for potential use in conditions such as anxiety and chronic pain. The company has also added Ketamir-2, an investigational oral ketamine analog being developed for potential treatment of depression and neuropathic pain. These candidates remain in development and are not approved medicines.AI Generated. May Contain Errors. Read More MIRA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreMIRA MarketRank™: 3.24551055184 of 5 starsMIRA Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 304th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingMIRA Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMIRA Pharmaceuticals has a consensus price target of $3.50, representing about 430.5% upside from its current price of $0.66.Amount of Analyst CoverageMIRA Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about MIRA Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of MIRA Pharmaceuticals is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MIRA Pharmaceuticals is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMIRA Pharmaceuticals has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MIRA Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.84% of the float of MIRA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMIRA Pharmaceuticals has a short interest ratio ("days to cover") of 1.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MIRA Pharmaceuticals has recently decreased by 19.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMIRA Pharmaceuticals does not currently pay a dividend.Dividend GrowthMIRA Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.27 News SentimentMIRA Pharmaceuticals has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MIRA Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MIRA Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.89% of the stock of MIRA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions35.16% of the stock of MIRA Pharmaceuticals is held by institutions.Read more about MIRA Pharmaceuticals' insider trading history. Receive MIRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MIRA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MIRA Stock News HeadlinesMIRA Pharmaceuticals (NASDAQ:MIRA) Shares Up 0.3% - Time to Buy?November 11, 2026 | americanbankingnews.comMIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With SemaglutideOctober 29, 2026 | globenewswire.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 15 at 1:00 AM | Behind the Markets (Ad)MIRA Pharmaceuticals, Inc. reports positive proof-of-concept results for oral SKNY-1 in obese miceOctober 28, 2026 | msn.comMIRA unveils promising preclinical data for oral obesity drugOctober 28, 2026 | tipranks.comMIRA Pharmaceuticals, Inc. Reports Mira-55 Demonstrates Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain StudyOctober 23, 2026 | marketscreener.comMMIRA Pharmaceuticals Advances MIRA-55 Toward 2027 IND Filing After Positive StudyOctober 22, 2026 | rttnews.comMIRA Pharmaceuticals, Inc. announces positive results from 21-day preclinical study of MIRA-55October 22, 2026 | msn.comSee More Headlines MIRA Stock Analysis - Frequently Asked Questions How have MIRA shares performed this year? MIRA Pharmaceuticals' stock was trading at $1.51 at the beginning of the year. Since then, MIRA shares have decreased by 56.3% and is now trading at $0.6598. How were MIRA Pharmaceuticals' earnings last quarter? MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) announced its quarterly earnings data on Thursday, November, 13th. The company reported ($1.18) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $1.07. When did MIRA Pharmaceuticals IPO? MIRA Pharmaceuticals (MIRA) raised $9 million in an initial public offering (IPO) on Wednesday, August 2nd 2023. The company issued 1,275,000 shares at a price of $6.00-$8.00 per share. Who are MIRA Pharmaceuticals' major shareholders? Top institutional investors of MIRA Pharmaceuticals include State Street Corp (0.18%). Insiders that own company stock include Erez Aminov and Brian Patrick Mcnulty. View institutional ownership trends. How do I buy shares of MIRA Pharmaceuticals? Shares of MIRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MIRA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that MIRA Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AST SpaceMobile (ASTS), ImmunityBio (IBRX), Palantir Technologies (PLTR), D-Wave Quantum (QBTS) and SoundHound AI (SOUN). Company Calendar Last Earnings8/12/2026Today11/15/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MIRA's financial health is in the Yellow zone, according to TradeSmith. MIRA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MIRA Previous SymbolNASDAQ:MIRA CIK1904286 Webmirapharmaceuticals.com Phone(813) 369-5150FaxN/AEmployees2Year Founded1978Price Target and Rating Average Price Target for MIRA Pharmaceuticals$3.50 High Price Target$3.50 Low Price Target$3.50 Potential Upside/Downside+430.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-106.95% Return on Assets-104.18% Debt Debt-to-Equity RatioN/A Current Ratio200.08 Quick Ratio200.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book2.64Miscellaneous Outstanding Shares42,020,000Free Float33,664,000Market Cap$27.72 million OptionableNot Optionable Beta1.65 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:MIRA) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
